MX2022014856A - Derivado de anticuerpo anti-nr1 humano. - Google Patents
Derivado de anticuerpo anti-nr1 humano.Info
- Publication number
- MX2022014856A MX2022014856A MX2022014856A MX2022014856A MX2022014856A MX 2022014856 A MX2022014856 A MX 2022014856A MX 2022014856 A MX2022014856 A MX 2022014856A MX 2022014856 A MX2022014856 A MX 2022014856A MX 2022014856 A MX2022014856 A MX 2022014856A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- human
- nmdar
- present
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020092105 | 2020-05-27 | ||
| PCT/JP2021/019929 WO2021241616A1 (ja) | 2020-05-27 | 2021-05-26 | 抗ヒトｎｒ１抗体誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014856A true MX2022014856A (es) | 2023-03-06 |
Family
ID=78744563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014856A MX2022014856A (es) | 2020-05-27 | 2021-05-26 | Derivado de anticuerpo anti-nr1 humano. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230220070A1 (https=) |
| EP (1) | EP4159859A4 (https=) |
| JP (1) | JPWO2021241616A1 (https=) |
| KR (1) | KR20230029671A (https=) |
| CN (2) | CN120737200A (https=) |
| AU (1) | AU2021281828A1 (https=) |
| BR (1) | BR112022023931A2 (https=) |
| CA (1) | CA3180470A1 (https=) |
| IL (1) | IL298537A (https=) |
| MX (1) | MX2022014856A (https=) |
| WO (1) | WO2021241616A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021241616A1 (ja) | 2020-05-27 | 2021-12-02 | アステラス製薬株式会社 | 抗ヒトｎｒ１抗体誘導体 |
| JP7730432B2 (ja) | 2022-10-19 | 2025-08-27 | アステラス製薬株式会社 | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 |
| AU2024242885A1 (en) * | 2023-03-30 | 2025-09-11 | Arialys Therapeutics, Inc. | Detection of autoantibodies against nr1 |
| WO2026033259A1 (en) * | 2024-08-05 | 2026-02-12 | Lys Therapeutics | Antibodies for treating neurological and neurovascular disorders |
| WO2026044177A1 (en) * | 2024-08-23 | 2026-02-26 | Janssen Biotech, Inc. | Methods of treatment with gprc5d antibodies with enhanced effector function |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| PT1718677E (pt) * | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| EP2805972A1 (en) | 2013-05-21 | 2014-11-26 | PAION Deutschland GmbH | Novel antibody useful in neurological or neurodegenerative disorders |
| RU2018109230A (ru) * | 2015-08-17 | 2019-09-19 | ДОЙЧЕС ЦЕНТРУМ ФЮР НОЙРОДЕГЕНЕРАТИВЕ ЭРКРАНКУНГЕН е.Ф. (ДЦНЭ) | Антитело, или фрагмент антитела, или неиммуноглобулиновый каркас, связывающийся с областью связывания антитела против рецептора n-метил-d-аспартата (nmda) |
| WO2019246071A1 (en) | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
| WO2020204977A1 (en) | 2019-03-29 | 2020-10-08 | Lankenau Institute For Medical Research | Anti-nmda receptor antibodies and methods of use |
| EP3999850A1 (en) | 2019-07-16 | 2022-05-25 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) | Nmda receptor constructs to detect and isolate nmdar autoantibodies |
| WO2021241616A1 (ja) | 2020-05-27 | 2021-12-02 | アステラス製薬株式会社 | 抗ヒトｎｒ１抗体誘導体 |
| CN114891091B (zh) | 2022-06-13 | 2024-04-26 | 四川携光生物技术有限公司 | 一种抗nmdar脑炎重组抗原及应用 |
| AU2024242885A1 (en) | 2023-03-30 | 2025-09-11 | Arialys Therapeutics, Inc. | Detection of autoantibodies against nr1 |
-
2021
- 2021-05-26 WO PCT/JP2021/019929 patent/WO2021241616A1/ja not_active Ceased
- 2021-05-26 CA CA3180470A patent/CA3180470A1/en active Pending
- 2021-05-26 JP JP2022526603A patent/JPWO2021241616A1/ja active Pending
- 2021-05-26 KR KR1020227045463A patent/KR20230029671A/ko active Pending
- 2021-05-26 IL IL298537A patent/IL298537A/en unknown
- 2021-05-26 CN CN202510915556.1A patent/CN120737200A/zh active Pending
- 2021-05-26 AU AU2021281828A patent/AU2021281828A1/en active Pending
- 2021-05-26 MX MX2022014856A patent/MX2022014856A/es unknown
- 2021-05-26 BR BR112022023931A patent/BR112022023931A2/pt unknown
- 2021-05-26 EP EP21812316.4A patent/EP4159859A4/en active Pending
- 2021-05-26 CN CN202180058596.9A patent/CN116133684B/zh active Active
-
2022
- 2022-11-17 US US18/056,635 patent/US20230220070A1/en active Pending
-
2024
- 2024-12-13 US US18/981,054 patent/US12331113B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230220070A1 (en) | 2023-07-13 |
| CN116133684A (zh) | 2023-05-16 |
| BR112022023931A2 (pt) | 2023-04-11 |
| AU2021281828A1 (en) | 2023-02-02 |
| CN120737200A (zh) | 2025-10-03 |
| JPWO2021241616A1 (https=) | 2021-12-02 |
| CN116133684B (zh) | 2025-07-18 |
| CA3180470A1 (en) | 2021-12-02 |
| WO2021241616A1 (ja) | 2021-12-02 |
| KR20230029671A (ko) | 2023-03-03 |
| IL298537A (en) | 2023-01-01 |
| EP4159859A1 (en) | 2023-04-05 |
| US20250122281A1 (en) | 2025-04-17 |
| EP4159859A4 (en) | 2024-07-10 |
| US12331113B2 (en) | 2025-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014856A (es) | Derivado de anticuerpo anti-nr1 humano. | |
| ES2096262T3 (es) | Nuevas cyclosporins modificadas en la posicion 1. | |
| MY197632A (en) | Method and composition for preventing, treating or relieving bone diseases | |
| EA201800499A1 (ru) | Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор | |
| PH12023552963A1 (en) | Compositions and methods for the treatment of depression | |
| MX2023013554A (es) | Regimenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogenicos. | |
| MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
| BR112022023413A2 (pt) | Tratamento de rugas faciais com toxina botulínica de alta dose e baixo volume | |
| MX2023005408A (es) | Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina. | |
| Sardone et al. | Effect of mechanical strain on the collagen VI pericellular matrix in anterior cruciate ligament fibroblasts | |
| WO2021067611A3 (en) | Compositions and methods for treating alzheimer's disease | |
| MX2023001678A (es) | Metodos para tratar esclerosis multiple con ocrelizumab. | |
| Malta | Biphasic relaxant curves to glyceryl trinitrate in rat aortic rings: evidence for two mechanisms of action | |
| MX2024004302A (es) | Metodos para realizar un cambio hemodinamico mediante la administracion de un anticuerpo anti-npr1. | |
| PH12020551203A1 (en) | Liquid composition for oral use containing collagen peptide, and method for alleviating the acidity of liquid composition for oral use | |
| WO2023009975A3 (en) | Fusion proteins comprising suppression of tumorigenicity 2 or interleukin-33, pharmaceutical compositions, and therapeutic applications | |
| MX2023010718A (es) | Composicion cosmetica prevista para el tratamiento de hiperpigmentacion de la piel y metodo de tratamiento que usa la composicion. | |
| MX2023013149A (es) | Anticuerpos anti-il-27 y usos de estos. | |
| MX2023013611A (es) | Fusiones de anticuerpo-protamina como compuestos de direccionamiento de una nanoparticula basada en protamina. | |
| JOP20220045A1 (ar) | تركيبة صيدلانية مائية من جسم مضاد ANTI-PD1 برولجوليماب prolgolimab واستخدامها | |
| MX2023004387A (es) | Cabello recubierto y uso del mismo. | |
| Woggon | The role of moclobemide in endogenous depression: a survey of recent data | |
| Moosavi et al. | Curcumin Ameliorates Aluminum Nanoparticle‐Induced Cognitive Impairment by Enhancing BDNF‐Akt Signaling in the Mouse Hippocampus | |
| John | Protein kinase G may exert pro-degradation inhibition on nitric oxide synthase | |
| Aldasoro et al. | AB0272 Switching from Etanercept original to Etanercept biosimilar. EXPERIENCE IN A TERTIARY HOSPITAL. |